Chemotherapy-associated hepatotoxicity: how concerned should we be?
Modern oncosurgical strategies are producing dramatic response rates and remarkable long-term survival rates for patients with hepatic colorectal cancer metastases. However, the increasing delivery of preoperative systemic chemotherapy to patients has coincided with recognition of possible chemotherapy-associated injury to the nontumoral liver. Although multiple groups have described gross changes in the appearance of the liver following systemic chemotherapy, the exact histopathologic lesions have not been clearly defined. A review of the literature on the topic indicates that host factors (e.g., diabetes mellitus and obesity) may be responsible for the development of liver injury as much as the drugs being delivered. With a lack of published evidence indicating that chemotherapy-associated liver injury results in adverse outcomes, several groups have recently questioned the clinical significance of this entity. This review describes the current understanding of this topic and seeks to answer the question of whether chemotherapy-associated liver injury actually impacts outcomes.
Aloia
Thomas A
TA
Department of Surgery, The Methodist Hospital Research Institute, 6550 Fannin Street, SM1661, Houston, TX 77030, USA. taaloia@tmhs.org
Fahy
Bridget N
BN
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D003920:Diabetes Mellitus / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009765:Obesity / Q000150:complications; D012307:Risk Factors; D013534:Survival
D000970:Antineoplastic Agents